Abstract
This article reviews the definition, incidence, pathological characteristics and natural history of low risk localised prostate cancer. Low risk disease is typically defined as clinical stage T1/T2a, biopsy Gleason score ≤6, PSA < 10. This risk classification has provided a useful system for reporting of outcomes and for the production of clinical guidelines. However, the low-risk disease is a broad category with a range of pathological characteristics and clinical behaviour. Many, but not all, low-risk prostate cancers are clinically insignificant, destined never to cause any harm. The challenge of managing low risk localized prostate cancer is to distinguish patients with clinically relevant cancers, who may benefit from radical treatment, from the remainder who do not need any intervention. The natural history of untreated low-risk localised prostate cancer has not been well studied, partly because it is a relatively recent entity, and partly because it has been standard practice for men with low risk disease to receive treatment. Data from watchful waiting in the pre-PSA era, modelling studies to take account of the lead time and overdiagnosis associated with PSA testing, and the early results of active surveillance can all provide insights into the likely natural history of low risk disease. There remains a major unmet need for markers of individual prostate cancer behaviour within the low-risk category. Such markers could be used to distinguish those men with truly indolent disease, suitable for observation, from those with significant prostate cancer that stand to benefit from treatment.
Similar content being viewed by others
References
Draisma G, Boer R, Otto SJ et al (2003) Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 95:868–878
Harnden P, Naylor B, Shelley MD, Clements H, Coles B, Mason MD (2008) The clinical management of patients with a small volume of prostatic cancer on biopsy: what are the risks of progression?: a systematic review and meta-analysis. Cancer 112:971–981
D’Amico AV, Whittington R, Malkowicz SB et al (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280:969–974
Zelefsky MJ, Fuks Z, Hunt M et al (2001) High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 166:876–881
Chism DB, Hanlon AL, Horwitz EM, Feigenberg SJ, Pollack A (2004) A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy. Int J Radiat Oncol Biol Phys 59:380–385
Kattan MW, Eastham JA, Wheeler TM et al (2003) Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol 170:1792–1797
Cooperberg MR, Lubeck DP, Meng MV, Mehta SS, Carroll PR (2004) The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol 22:2141–2149
Master VA, Chi T, Simko JP, Weinberg V, Carroll PR (2005) The independent impact of extended pattern biopsy on prostate cancer stage migration. J Urol 174:1789–1793 discussion 1793
Stamey TA, Freiha FS, McNeal JE, Redwine EA, Whittemore AS, Schmid HP (1993) Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 71:933–938
Winkler MH, Livni N, Mannion EM, Hrouda D, Christmas T (2007) Characteristics of incidental prostatic adenocarcinoma in contemporary radical cystoprostatectomy specimens. BJU Int 99:554–558
Epstein JI, Walsh PC, Carmichael M, Brendler CB (1994) Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 271:368–374
Haas GP, Delongchamps NB, Jones RF et al (2007) Needle biopsies on autopsy prostates: sensitivity of cancer detection based on true prevalence. J Natl Cancer Inst 99:1484–1489
Stephenson AJ, Kattan MW, Eastham JA et al. (2008) Prostate cancer-specific mortality after radical prostatectomy in the prostate-specific antigen era. Abstract no. 9, Proceedings ASCO GU 2008
Albertsen PC, Hanley JA, Gleason DF, Barry MJ (1998) Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 280:975–980
Albertsen PC, Hanley JA, Fine J (2005) 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 293:2095–2101
Albertsen PC, Hanley JA, Barrows GH et al (2005) Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst 97:1248–1253
Johansson JE, Holmberg L, Johansson S, Bergstrom R, Adami HO (1997) Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA 277:467–471
Chodak GW, Thisted RA, Gerber GS et al (1994) Results of conservative management of clinically localized prostate cancer. N Engl J Med 330:242–248
Cuzick J, Fisher G, Kattan MW et al (2006) Long-term outcome among men with conservatively treated localised prostate cancer. Br J Cancer 95:1186–1194
Bill-Axelson A, Holmberg L, Ruutu M et al (2005) Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 352:1977–1984
Wilt TJ, Brawer MK (1995) Early intervention or expectant management for prostate cancer. The Prostate Cancer Intervention Versus Observation Trial (PIVOT): a randomized trial comparing radical prostatectomy with expectant management for the treatment of clinically localized prostate cancer. Semin Urol 13:130–136
Donovan J, Hamdy F, Neal D et al (2003) Prostate Testing for Cancer and Treatment (ProtecT) feasibility study. Health Technol Assess 7:1–88
Parker C, Muston D, Melia J, Moss S, Dearnaley D (2006) A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival. Br J Cancer 94:1361–1368
Singer PA, Tasch ES, Stocking C, Rubin S, Siegler M, Weichselbaum R (1991) Sex or survival: trade-offs between quality and quantity of life. J Clin Oncol 9:328–334
Klotz L (2005) Active surveillance for prostate cancer: for whom? J Clin Oncol 23:8165–8169
Roemeling S, Roobol MJ, de Vries SH et al (2007) Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial: characteristics, PSA doubling times, and outcome. Eur Urol 51:1244–1250 Discussion 1251
van As NJ, Parker CC (2007) Active surveillance with selective radical treatment for localized prostate cancer. Cancer J 13(5):289–294
Khatami A, Aus G, Damber JE, Lilja H, Lodding P, Hugosson J (2007) PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: results from the European randomized study of screening for prostate cancer, Sweden section. Int J Cancer 120:170–174
Carter HB, Kettermann A, Warlick C et al (2007) Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol 178:2359–2364 Discussion 2364–2355
de Vries SH, Raaijmakers R, Kranse R, Blijenberg BG, Schroder FH (2004) Prostate cancer characteristics and prostate specific antigen changes in screening detected patients initially treated with a watchful waiting policy. J Urol 172:2193–2196
Hardie C, Parker C, Norman A et al (2005) Early outcomes of active surveillance for localized prostate cancer. BJU Int 95:956–960
Steuber T, Vickers AJ, Serio AM et al (2007) Comparison of free and total forms of serum human kallikrein 2 and prostate-specific antigen for prediction of locally advanced and recurrent prostate cancer. Clin Chem 53:233–240
Raaijmakers R, de Vries SH, Blijenberg BG et al (2007) hK2 and free PSA, a prognostic combination in predicting minimal prostate cancer in screen-detected men within the PSA range 4–10 ng/ml. Eur Urol 52:1358–1364
Fall K, Garmo H, Andren O et al (2007) Prostate-specific antigen levels as a predictor of lethal prostate cancer. J Natl Cancer Inst 99:526–532
Quinn DI, Henshall SM, Sutherland RL (2005) Molecular markers of prostate cancer outcome. Eur J Cancer 41:858–887
Borre M, Stausbol-Gron B, Overgaard J (2000) p53 accumulation associated with bcl-2, the proliferation marker MIB-1 and survival in patients with prostate cancer subjected to watchful waiting. J Urol 164:716–721
Jhavar S, Corbishley CM, Dearnaley D et al (2005) Construction of tissue microarrays from prostate needle biopsy specimens. Br J Cancer 93:478–482
Acknowledgments
This work was undertaken in The Royal Marsden NHS Foundation Trust who received a proportion of its funding from the NHS Executive; the views expressed in this publication are those of the authors and not necessarily those of the NHS Executive. This work was supported by the Institute of Cancer Research, the Cancer Research UK Section of Radiotherapy (CUK) grant number C46/A2131 and NCRI South of England Prostate Cancer Collaborative.
Conflict of interest statement
There is no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
O’Donnell, H., Parker, C. What is low-risk prostate cancer and what is its natural history?. World J Urol 26, 415–422 (2008). https://doi.org/10.1007/s00345-008-0277-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00345-008-0277-9